NeuroSense Therapeutics has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive trading days. The company has been granted a grace period until February 24, 2025, to regain compliance by maintaining a closing bid price of $1.00 or above for at least 10 consecutive business days.The notification has no immediate impact on NeuroSense's Nasdaq listing or trading status, and shares will continue trading under the symbol "NRSN". If compliance is not achieved by the deadline, the company may be eligible for an additional 180-day extension, provided it meets other Nasdaq Capital Market listing requirements. The company's business operations remain unaffected by this notification.

NeuroSense Therapeutics has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive trading days. The company has been granted a grace period until February 24, 2025, to regain compliance by maintaining a closing bid price of $1.00 or above for at least 10 consecutive business days.The notification has no immediate impact on NeuroSense's Nasdaq listing or trading status, and shares will continue trading under the symbol "NRSN". If compliance is not achieved by the deadline, the company may be eligible for an additional 180-day extension, provided it meets other Nasdaq Capital Market listing requirements. The company's business operations remain unaffected by this notification.